Matritech submits 510(k) clearance for NuMa test:
This article was originally published in Clinica
Executive Summary
Matritech has submitted a 510(k) premarket notification to the FDA for its blood-based NuMa test kit. The test is used in the management of colon cancer and is based on the US company's Nuclear Matrix Protein (NMP) technology which correlates levels of NMPs in body fluids to the presence of cancer.